Related Experiment Video
Updated: Feb 14, 2026
05:58
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
Published on: June 25, 2019
8.0K
Control of insulin secretion by GLP-1
Ben Jones1, Stephen R Bloom1, Teresa Buenaventura2
1Section of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK.
Peptides
|February 8, 2018
Summary
Glucagon-like peptide-1 receptor (GLP-1R) research reveals biased agonists may improve type 2 diabetes treatment. Lower affinity GLP-1R agonists show greater insulin secretion and improved glycemic control with fewer side effects.
Area of Science:
- Endocrinology
- Molecular Pharmacology
- Cell Biology
Background:
- Glucagon-like peptide-1 (GLP-1) and its analogues are crucial for treating type 2 diabetes (T2D) and obesity.
- GLP-1 receptor (GLP-1R) activation stimulates insulin secretion, improving glycemic control.
- Current GLP-1 analogues can cause side effects like nausea, limiting therapeutic potential.
Purpose of the Study:
- To explore GLP-1R signaling and trafficking in pancreatic beta cells.
- To investigate biased agonism at the GLP-1R for improved therapeutic compounds.
- To understand how ligand-receptor interactions affect insulin secretion and glycemic control.
Main Methods:
- Analysis of GLP-1R signaling pathways, including cAMP generation and beta-arrestin/ERK1/2 recruitment.
- Investigation of GLP-1R trafficking and internalization in response to different agonists.
- Comparison of insulin secretion and glycemic effects of various GLP-1R agonists.
Main Results:
- Biased agonism at the GLP-1R, favoring cAMP generation over beta-arrestin/ERK1/2 activation, is a promising strategy.
- Lower-affinity GLP-1R agonists that induce less receptor internalization resulted in greater insulin secretion.
- These findings correlated with enhanced improvements in glycemic control compared to parent compounds.
Conclusions:
- Targeting GLP-1R biased signaling offers a novel approach for developing more effective T2D and obesity treatments.
- Reduced GLP-1R internalization by specific agonists may lead to improved therapeutic efficacy and tolerability.
- Further research into GLP-1R ligand interactions can optimize treatment strategies for metabolic diseases.
More Related Videos
Related Concept Videos
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.6K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.6K
01:05Insulin Secretory Vesicles
7.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.0K
01:28Insulin: The Receptor and Signaling Pathways
3.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.5K
01:27Insulin Formulations: Types and Delivery
800
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
800
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.5K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.5K
01:19Regulation of Hormone Secretion
7.0K
Regulation of hormone secretion is a finely tuned orchestration driven by various types of stimuli, encompassing neural, humoral, and hormonal signals. Environmental cues instigate neural stimuli, where action potentials traverse nerve fibers to reach their designated targets. An illustrative scenario is the body's response to stress, wherein the sympathetic nervous system releases epinephrine from the adrenal glands, inducing the well-known 'fight or flight' reaction.
Humoral...
Humoral...
7.0K